Literature DB >> 14585367

Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection.

Carmen Canals1, Rodrigo Martino, Ana Sureda, Albert Altés, Javier Briones, Maricel Subirá, Idoia Ancín, Gregorio Martín-Henao, Salut Brunet, Jorge Sierra.   

Abstract

OBJECTIVES: The aim of this study was to compare two approaches used to reduce transplant-related mortality (TRM) after allogeneic peripheral blood stem cell transplantation (allo-PBSCT) in elderly patients. PATIENTS AND METHODS: Data from 50 patients, 45 years of age or older, consecutively treated with an HLA-identical sibling allo-PBSCT at the Hospital de Sant Pau were analyzed. We have compared the outcome of patients treated with conventional myeloablative regimens and CD34(+)-selected cells (CD34(+) group; n=23) with those receiving reduced-intensity conditioning regimens, consisting of fludarabine (150 mg/m(2)) plus an alkylating agent, followed by unmanipulated grafts (RIC group; n=27). Patient characteristics were well balanced between the two groups, although patients in the RIC group were slightly older.
RESULTS: The incidence of acute graft-vs-host disease (GVHD) was similar in both groups. The 1-year cumulative incidence of extensive chronic GVHD was 38% in the RIC group and 17% in the CD34(+) group (p=0.2). After a median follow-up of 28 months, there were no differences in the relapse rate. Patients in the RIC group had a lower TRM, with a cumulative incidence of 7% vs 30% at 6 months and 15% vs 39% at 1 year (p=0.05). The Kaplan-Meier estimates of PFS at 2 years was 67% in the RIC group and 43% in the CD34(+) group (p=0.09) and the OS was 69% vs 43% (p=0.05), respectively.
CONCLUSION: CD34(+) cell selection reduced the risk of extensive cGVHD but was associated with a higher TRM. Although the number of patients is limited, our study suggests that this approach should be restricted to relatively young patients, as better outcomes can be achieved in elderly patients using RIC strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585367     DOI: 10.1016/s0301-472x(03)00223-6

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  4 in total

1.  Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplants.

Authors:  B Thyagarajan; S Jackson; S Basu; P Jacobson; M D Gross; D J Weisdorf; M Arora
Journal:  Int J Immunogenet       Date:  2012-05-30       Impact factor: 1.466

2.  Long-term results after transplantation of CD34+ selected (CellPro) versus unselected peripheral blood progenitor cells (PBPC) from related allogeneic donors.

Authors:  Hans-Georg Kopp; Stefan Wirths; Christoph Faul; Wolfgang Bethge; Stefan Scheding; Wolfram Brugger; Lothar Kanz; Wichard Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-09       Impact factor: 4.553

3.  Association between genetic variants in the base excision repair pathway and outcomes after hematopoietic cell transplantations.

Authors:  Bharat Thyagarajan; Bruce Lindgren; Saonli Basu; Sriharsha Nagaraj; Myron D Gross; Daniel J Weisdorf; Mukta Arora
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-11       Impact factor: 5.742

Review 4.  Non-myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Nonniekaye Shelburne; Margaret Bevans
Journal:  Semin Oncol Nurs       Date:  2009-05       Impact factor: 2.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.